Skip to main content

What the FDA labels say about taking them together

Ensitrelvir and lurasidone

Ensitrelvir's FDA label of June 3, 2026 names lurasidone in its drug interactions section; the lurasidone label PlainMeds reads does not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated due to serious and/or life-threatening reactions, such as cardiac arrhythmias.”

Check it at the source: the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.); the lurasidone FDA label on DailyMed (effective January 31, 2025, Sumitomo Pharma America, Inc.).

What does the ensitrelvir label say about lurasidone?

Ensitrelvir label, drug interactions

Drug Class: Antipsychotics; Drug (s) within Class: lurasidone, pimozide; Effect on Drug Concentration: ↑ lurasidone, pimozide; Clinical Comment: Co-administration is contraindicated due to serious and/or life-threatening reactions, such as cardiac arrhythmias.

Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed

What does the lurasidone label say about ensitrelvir?

Lurasidone's label (effective January 31, 2025) does not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Latuda), NDA200603 (Sunovion Pharms Inc), as published by Sumitomo Pharma America, Inc., effective January 31, 2025 (SPL set afad3051-9df2-4c54-9684-e8262a133af8), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Ensitrelvir generic labelers
28Lurasidone generic labelers
EnsitrelvirLurasidone
Labeled forCOVID-19Schizophrenia, Bipolar disorder, Depression
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.142 per tablet 20 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?